Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | NPY4R | P50391 | 6/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.36 |
| ▸ | NPY1R | P25929 | 5/20 | 0.36 |
| ▸ | NPY2R | P49146 | 3/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28933203 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29875551 | 0.93 | C3AR1 (0.40) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29533805 | 0.92 | QRFPR (0.43) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29534033 | 0.92 | NPY4R (0.41) | PTGS1GSTK1FNTAFNTBPGGT1B | |
| SCHEMBL29595677 | 0.91 | TFPI (0.38) | PTGS1GSTK1SLC15A2 | |
| SCHEMBL29630598 | 0.89 | QRFPR (0.42) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29405094 | 0.88 | ITGB3 (0.38) | PTGS1GSTK1QRFPRNPY4RNPY5R | |
| SCHEMBL31593243 | 0.88 | SLC15A2 (0.43) | QRFPRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL12646501 | 0.88 | ITGB3 (0.38) | PTGS1GSTK1QRFPRNPY4RNPY5R | |
| SCHEMBL30481161 | 0.87 | NOD1 (0.43) | QRFPRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | claimed |
| CN-115605215-A | Treatment to improve or reduce impairment of mitochondrial function | 急速制药有限责任公司（US） | 2023-01-13 | — | — | CN | claimed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| JP-2025519534-A | — | ジェニアス ファーマ エルエルシー | 2025-06-26 | — | — | JP | disclosed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
| WO-2023239716-A3 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-115605215-A | Treatment to improve or reduce impairment of mitochondrial function | 急速制药有限责任公司（US） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | PTGS1 596/4885GSTK1 101/4885FNTA 3181/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | PTGS1 596/4885GSTK1 101/4885FNTA 3181/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | PTGS1 596/4885GSTK1 101/4885FNTA 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.